Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study von Steinfeld, Serge D, Tant, Laure, Burmester, Gerd R, Teoh, Nick K W, Wegener, William A, Goldenberg, David M, Pradier, Olivier

Volltext

Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma von STRAUSS, Sandra J, MORSCHHAUSER, Frank, TEOH, Nick K. W, GOLDENBERG, David M, LISTER, T. Andrew, RECH, Juergen, REPP, Roland, SOLAL-CELIGNY, Philippe, ZINZANI, Pier L, ENGERT, Andreas, COIFFIER, Bernard, HOELZER, Dieter F, WEGENER, William A

Volltext

Responder rates von Steinfeld, Serge D, Tant, Laure, Burmester, Gerd R, Teoh, Nick KW, Wegener, William A, Goldenberg, David M, Pradier, Olivier

Volltext bestellen

Peripheral B-cell counts von Steinfeld, Serge D, Tant, Laure, Burmester, Gerd R, Teoh, Nick KW, Wegener, William A, Goldenberg, David M, Pradier, Olivier

Volltext bestellen

Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin’s lymphoma von NEGREA, George O, ELSTROM, Rebecca, ALLEN, Steven L, RAI, Kanti R, ABBASI, Rashid M, FARBER, Charles M, TEOH, Nick, HORNE, Heather, WEGENER, William A, GOLDENBERG, David M

Volltext